Skip to main content
Top
Published in: BMC Medicine 1/2019

Open Access 01-12-2019 | Coronary Heart Disease | Research article

Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis

Authors: Johanna A. Damen, Romin Pajouheshnia, Pauline Heus, Karel G. M. Moons, Johannes B. Reitsma, Rob J. P. M. Scholten, Lotty Hooft, Thomas P. A. Debray

Published in: BMC Medicine | Issue 1/2019

Login to get access

Abstract

Background

The Framingham risk models and pooled cohort equations (PCE) are widely used and advocated in guidelines for predicting 10-year risk of developing coronary heart disease (CHD) and cardiovascular disease (CVD) in the general population. Over the past few decades, these models have been extensively validated within different populations, which provided mounting evidence that local tailoring is often necessary to obtain accurate predictions. The objective is to systematically review and summarize the predictive performance of three widely advocated cardiovascular risk prediction models (Framingham Wilson 1998, Framingham ATP III 2002 and PCE 2013) in men and women separately, to assess the generalizability of performance across different subgroups and geographical regions, and to determine sources of heterogeneity in the findings across studies.

Methods

A search was performed in October 2017 to identify studies investigating the predictive performance of the aforementioned models. Studies were included if they externally validated one or more of the original models in the general population for the same outcome as the original model. We assessed risk of bias for each validation and extracted data on population characteristics and model performance. Performance estimates (observed versus expected (OE) ratio and c-statistic) were summarized using a random effects models and sources of heterogeneity were explored with meta-regression.

Results

The search identified 1585 studies, of which 38 were included, describing a total of 112 external validations. Results indicate that, on average, all models overestimate the 10-year risk of CHD and CVD (pooled OE ratio ranged from 0.58 (95% CI 0.43–0.73; Wilson men) to 0.79 (95% CI 0.60–0.97; ATP III women)). Overestimation was most pronounced for high-risk individuals and European populations. Further, discriminative performance was better in women for all models. There was considerable heterogeneity in the c-statistic between studies, likely due to differences in population characteristics.

Conclusions

The Framingham Wilson, ATP III and PCE discriminate comparably well but all overestimate the risk of developing CVD, especially in higher risk populations. Because the extent of miscalibration substantially varied across settings, we highly recommend that researchers further explore reasons for overprediction and that the models be updated for specific populations.
Appendix
Available only for authorised users
Literature
2.
go back to reference Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.PubMedCrossRef Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.PubMedCrossRef
3.
go back to reference National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.CrossRef National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.CrossRef
4.
go back to reference Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMedCrossRef Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMedCrossRef
5.
go back to reference Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, Lassale CM, Siontis GC, Chiocchia V, Roberts C, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353:i2416.PubMedPubMedCentralCrossRef Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, Lassale CM, Siontis GC, Chiocchia V, Roberts C, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353:i2416.PubMedPubMedCentralCrossRef
6.
go back to reference Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416–23.PubMedCrossRef Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416–23.PubMedCrossRef
7.
go back to reference DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, Kronmal RA, McClelland RL, Nasir K, Blaha MJ. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4):266–75. DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, Kronmal RA, McClelland RL, Nasir K, Blaha MJ. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4):266–75.
8.
go back to reference Reissigova J, Zvarova J. The Framingham risk function underestimated absolute coronary heart disease risk in Czech men. Methods Inf Med. 2007;46(1):43–9.PubMedCrossRef Reissigova J, Zvarova J. The Framingham risk function underestimated absolute coronary heart disease risk in Czech men. Methods Inf Med. 2007;46(1):43–9.PubMedCrossRef
9.
go back to reference Comin E, Solanas P, Cabezas C, Subirana I, Ramos R, Gene-Badia J, Cordon F, Grau M, Cabre-Vila JJ, Marrugat J. Estimating cardiovascular risk in Spain using different algorithms. Rev Esp Cardiol. 2007;60(7):693–702.PubMedCrossRef Comin E, Solanas P, Cabezas C, Subirana I, Ramos R, Gene-Badia J, Cordon F, Grau M, Cabre-Vila JJ, Marrugat J. Estimating cardiovascular risk in Spain using different algorithms. Rev Esp Cardiol. 2007;60(7):693–702.PubMedCrossRef
10.
go back to reference Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73.PubMedCrossRef Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73.PubMedCrossRef
11.
go back to reference D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7.PubMedCrossRef D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7.PubMedCrossRef
12.
go back to reference Beswick AD, Brindle P, Fahey T, Ebrahim S. A systematic review of risk scoring methods and clinical decision aids used in the primary prevention of coronary heart disease (supplement). London: Royal College of General Practitioners; 2008. Beswick AD, Brindle P, Fahey T, Ebrahim S. A systematic review of risk scoring methods and clinical decision aids used in the primary prevention of coronary heart disease (supplement). London: Royal College of General Practitioners; 2008.
13.
go back to reference Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752–9.PubMedPubMedCentralCrossRef Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752–9.PubMedPubMedCentralCrossRef
14.
go back to reference Eichler K, Puhan MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J. 2007;153(5):722–31 731.e721–728.PubMedCrossRef Eichler K, Puhan MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J. 2007;153(5):722–31 731.e721–728.PubMedCrossRef
15.
go back to reference Cook NR, Ridker PM. Calibration of the pooled cohort equations for atherosclerotic cardiovascular disease: an update. Ann Intern Med. 2016;165(11):786–94.PubMedCrossRef Cook NR, Ridker PM. Calibration of the pooled cohort equations for atherosclerotic cardiovascular disease: an update. Ann Intern Med. 2016;165(11):786–94.PubMedCrossRef
16.
go back to reference Debray TP, Damen JA, Snell KI, Ensor J, Hooft L, Reitsma JB, Riley RD, Moons KG. A guide to systematic review and meta-analysis of prediction model performance. BMJ. 2017;356:i6460.PubMedCrossRef Debray TP, Damen JA, Snell KI, Ensor J, Hooft L, Reitsma JB, Riley RD, Moons KG. A guide to systematic review and meta-analysis of prediction model performance. BMJ. 2017;356:i6460.PubMedCrossRef
17.
go back to reference Harrell F. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Switzerland: Springer; 2015. Harrell F. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Switzerland: Springer; 2015.
18.
go back to reference Steyerberg E. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer-Verlag; 2008. Steyerberg E. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer-Verlag; 2008.
19.
go back to reference Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–31.PubMedPubMedCentralCrossRef Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–31.PubMedPubMedCentralCrossRef
20.
go back to reference Su TL, Jaki T, Hickey GL, Buchan I, Sperrin M. A review of statistical updating methods for clinical prediction models. Stat Methods Med Res. 2018;27(1):185–197. Su TL, Jaki T, Hickey GL, Buchan I, Sperrin M. A review of statistical updating methods for clinical prediction models. Stat Methods Med Res. 2018;27(1):185–197.
21.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.PubMedCrossRef Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.PubMedCrossRef
22.
go back to reference Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.PubMedPubMedCentralCrossRef Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.PubMedPubMedCentralCrossRef
23.
go back to reference Moons KG, de Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, Reitsma JB, Collins GS. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med. 2014;11(10):e1001744.PubMedPubMedCentralCrossRef Moons KG, de Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, Reitsma JB, Collins GS. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med. 2014;11(10):e1001744.PubMedPubMedCentralCrossRef
24.
go back to reference Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med. 2004;23(16):2567–86.PubMedCrossRef Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med. 2004;23(16):2567–86.PubMedCrossRef
25.
go back to reference Janssen KJ, Moons KG, Kalkman CJ, Grobbee DE, Vergouwe Y. Updating methods improved the performance of a clinical prediction model in new patients. J Clin Epidemiol. 2008;61(1):76–86.PubMedCrossRef Janssen KJ, Moons KG, Kalkman CJ, Grobbee DE, Vergouwe Y. Updating methods improved the performance of a clinical prediction model in new patients. J Clin Epidemiol. 2008;61(1):76–86.PubMedCrossRef
26.
go back to reference Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997;315(7109):635–40. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997;315(7109):635–40.
27.
go back to reference Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170(1):51–8. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170(1):51–8.
28.
go back to reference Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1–33. Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1–33.
29.
go back to reference Snell KI, Ensor J, Debray TP, Moons KG, Riley RD. Meta-analysis of prediction model performance across multiple studies: Which scale helps ensure between-study normality for the C-statistic and calibration measures? Stat Methods Med Res. 2018;27(11):3505–22. Snell KI, Ensor J, Debray TP, Moons KG, Riley RD. Meta-analysis of prediction model performance across multiple studies: Which scale helps ensure between-study normality for the C-statistic and calibration measures? Stat Methods Med Res. 2018;27(11):3505–22.
30.
go back to reference Snell KI, Hua H, Debray TP, Ensor J, Look MP, Moons KG, Riley RD. Multivariate meta-analysis of individual participant data helped externally validate the performance and implementation of a prediction model. J Clin Epidemiol 2016;69:40–50. Snell KI, Hua H, Debray TP, Ensor J, Look MP, Moons KG, Riley RD. Multivariate meta-analysis of individual participant data helped externally validate the performance and implementation of a prediction model. J Clin Epidemiol 2016;69:40–50.
31.
go back to reference R Core Team. R: A language and environment for statistical computing. In: R Core Team. Vienna: R Foundation for Statistical Computing; 2016. R Core Team. R: A language and environment for statistical computing. In: R Core Team. Vienna: R Foundation for Statistical Computing; 2016.
32.
go back to reference Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.CrossRef Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.CrossRef
33.
go back to reference Gasparrini A, Armstrong B, Kenward MG. Multivariate meta-analysis for non-linear and other multi-parameter associations. Stat Med. 2012;31(29):3821–39.PubMedPubMedCentralCrossRef Gasparrini A, Armstrong B, Kenward MG. Multivariate meta-analysis for non-linear and other multi-parameter associations. Stat Med. 2012;31(29):3821–39.PubMedPubMedCentralCrossRef
34.
go back to reference Debray TP. Metamisc: Diagnostic and Prognostic Meta-Analysis; 2017. Debray TP. Metamisc: Diagnostic and Prognostic Meta-Analysis; 2017.
35.
go back to reference Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1–48. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1–48.
36.
go back to reference Andersson C, Enserro D, Larson MG, Xanthakis V, Vasan RS. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4(4):e001888. Andersson C, Enserro D, Larson MG, Xanthakis V, Vasan RS. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4(4):e001888.
37.
go back to reference Buitrago F, Calvo-Hueros JI, Canon-Barroso L, Pozuelos-Estrada G, Molina-Martinez L, Espigares-Arroyo M, Galan-Gonzalez JA, Lillo-Bravo FJ. Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation study. Ann Fam Med. 2011;9(5):431–8.PubMedPubMedCentralCrossRef Buitrago F, Calvo-Hueros JI, Canon-Barroso L, Pozuelos-Estrada G, Molina-Martinez L, Espigares-Arroyo M, Galan-Gonzalez JA, Lillo-Bravo FJ. Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation study. Ann Fam Med. 2011;9(5):431–8.PubMedPubMedCentralCrossRef
38.
go back to reference Chia YC, Lim HM, Ching SM. Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study. BMC Cardiovasc Disord. 2014;14:163.PubMedPubMedCentralCrossRef Chia YC, Lim HM, Ching SM. Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study. BMC Cardiovasc Disord. 2014;14:163.PubMedPubMedCentralCrossRef
39.
go back to reference Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med. 2014;174(12):1964–71.PubMedPubMedCentralCrossRef Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med. 2014;174(12):1964–71.PubMedPubMedCentralCrossRef
40.
go back to reference Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181(1):93–100.PubMedCrossRef Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181(1):93–100.PubMedCrossRef
41.
go back to reference DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, Kronmal RA, McClelland RL, Blaha MJ. Risk score overestimation: The impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38(8):598–608. DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, Kronmal RA, McClelland RL, Blaha MJ. Risk score overestimation: The impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38(8):598–608.
42.
go back to reference De Las Heras Gala T, Geisel MH, Peters A, Thorand B, Baumert J, Lehmann N, Jockel KH, Moebus S, Erbel R, Mahabadi AA, et al. Recalibration of the ACC/AHA risk score in two population-based German cohorts. PLoS One. 2016;11(10):e0164688.PubMedCrossRef De Las Heras Gala T, Geisel MH, Peters A, Thorand B, Baumert J, Lehmann N, Jockel KH, Moebus S, Erbel R, Mahabadi AA, et al. Recalibration of the ACC/AHA risk score in two population-based German cohorts. PLoS One. 2016;11(10):e0164688.PubMedCrossRef
43.
go back to reference Emdin CA, Khera AV, Natarajan P, Klarin D, Baber U, Mehran R, Rader DJ, Fuster V, Kathiresan S. Evaluation of the pooled cohort equations for prediction of cardiovascular risk in a contemporary prospective cohort. Am J Cardiol. 2017;119(6):881–5.PubMedCrossRef Emdin CA, Khera AV, Natarajan P, Klarin D, Baber U, Mehran R, Rader DJ, Fuster V, Kathiresan S. Evaluation of the pooled cohort equations for prediction of cardiovascular risk in a contemporary prospective cohort. Am J Cardiol. 2017;119(6):881–5.PubMedCrossRef
44.
go back to reference Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, Haas B, Yarnell J, Bingham A, Amouyel P, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24(21):1903–11.PubMedCrossRef Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, Haas B, Yarnell J, Bingham A, Amouyel P, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24(21):1903–11.PubMedCrossRef
45.
go back to reference Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, Sega R, Pilotto L, Palmieri L, Giampaoli S, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol. 2005;34(2):413–21.PubMedCrossRef Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, Sega R, Pilotto L, Palmieri L, Giampaoli S, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol. 2005;34(2):413–21.PubMedCrossRef
46.
go back to reference Jee SH, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, Seung KB, Mok Y, Jung KJ, Kimm H, et al. A coronary heart disease prediction model: The Korean heart study. BMJ Open. 2014;4(5):e005025.PubMedPubMedCentralCrossRef Jee SH, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, Seung KB, Mok Y, Jung KJ, Kimm H, et al. A coronary heart disease prediction model: The Korean heart study. BMJ Open. 2014;4(5):e005025.PubMedPubMedCentralCrossRef
47.
go back to reference Jung KJ, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, Seung KB, Kim HK, Yun YD, Choi SH, et al. The ACC/AHA 2013 pooled cohort equations compared to a Korean Risk Prediction Model for atherosclerotic cardiovascular disease. Atherosclerosis. 2015;242(1):367–75.PubMedCrossRef Jung KJ, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, Seung KB, Kim HK, Yun YD, Choi SH, et al. The ACC/AHA 2013 pooled cohort equations compared to a Korean Risk Prediction Model for atherosclerotic cardiovascular disease. Atherosclerosis. 2015;242(1):367–75.PubMedCrossRef
48.
go back to reference Khalili D, Asgari S, Hadaegh F, Steyerberg EW, Rahimi K, Fahimfar N, Azizi F. A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study. Int J Cardiol. 2015;184(1):587–94.PubMedCrossRef Khalili D, Asgari S, Hadaegh F, Steyerberg EW, Rahimi K, Fahimfar N, Azizi F. A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study. Int J Cardiol. 2015;184(1):587–94.PubMedCrossRef
49.
go back to reference Koller MT, Steyerberg EW, Wolbers M, Stijnen T, Bucher HC, MGM H, JCM W. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am Heart J. 2007;154(1):87–93.PubMedCrossRef Koller MT, Steyerberg EW, Wolbers M, Stijnen T, Bucher HC, MGM H, JCM W. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am Heart J. 2007;154(1):87–93.PubMedCrossRef
50.
go back to reference Koller MT, Leening MJG, Wolbers M, Steyerberg EW, Hunink MGM, Schoop R, Hofman A, Bucher HC, Psaty BM, Lloyd-Jones DM, et al. Development and validation of a coronary risk prediction model for older U.S. and European persons in the cardiovascular health study and the Rotterdam Study. Ann Intern Med. 2012;157(6):389–97. Koller MT, Leening MJG, Wolbers M, Steyerberg EW, Hunink MGM, Schoop R, Hofman A, Bucher HC, Psaty BM, Lloyd-Jones DM, et al. Development and validation of a coronary risk prediction model for older U.S. and European persons in the cardiovascular health study and the Rotterdam Study. Ann Intern Med. 2012;157(6):389–97.
51.
go back to reference Lee CH, Woo YC, Lam JKY, Fong CHY, Cheung BMY, Lam KSL, Tan KCB. Validation of the pooled cohort equations in a long-term cohort study of Hong Kong Chinese. J Clin Lipidol. 2015;9(5):640–6. Lee CH, Woo YC, Lam JKY, Fong CHY, Cheung BMY, Lam KSL, Tan KCB. Validation of the pooled cohort equations in a long-term cohort study of Hong Kong Chinese. J Clin Lipidol. 2015;9(5):640–6.
52.
go back to reference Lloyd-Jones DM, Wilson PWF, Larson MG, Beiser A, Leip EP, D’Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20–4. Lloyd-Jones DM, Wilson PWF, Larson MG, Beiser A, Leip EP, D’Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20–4.
53.
go back to reference Mainous AG 3rd, Koopman RJ, Diaz VA, Everett CJ, Wilson PWF, Tilley BC. A coronary heart disease risk score based on patient-reported information. Am J Cardiol. 2007;99(9):1236–41.PubMedPubMedCentralCrossRef Mainous AG 3rd, Koopman RJ, Diaz VA, Everett CJ, Wilson PWF, Tilley BC. A coronary heart disease risk score based on patient-reported information. Am J Cardiol. 2007;99(9):1236–41.PubMedPubMedCentralCrossRef
54.
go back to reference Marrugat J, Subirana I, Comin E, Cabezas C, Vila J, Elosua R, Nam BH, Ramos R, Sala J, Solanas P, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007;61(1):40–7.PubMedPubMedCentralCrossRef Marrugat J, Subirana I, Comin E, Cabezas C, Vila J, Elosua R, Nam BH, Ramos R, Sala J, Solanas P, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007;61(1):40–7.PubMedPubMedCentralCrossRef
55.
go back to reference Mortensen MB, Afzal S, Nordestgaard BG, Falk E. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. J Am Coll Cardiol. 2015;66(24):2699–709.PubMedCrossRef Mortensen MB, Afzal S, Nordestgaard BG, Falk E. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. J Am Coll Cardiol. 2015;66(24):2699–709.PubMedCrossRef
56.
go back to reference Mortensen MB, Nordestgaard BG, Afzal S, Falk E. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. Eur Heart J. 2017;38(8):586–94.PubMed Mortensen MB, Nordestgaard BG, Afzal S, Falk E. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. Eur Heart J. 2017;38(8):586–94.PubMed
57.
go back to reference Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311(14):1406–15.PubMedPubMedCentralCrossRef Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311(14):1406–15.PubMedPubMedCentralCrossRef
58.
go back to reference Pike MM, Decker PA, Larson NB, St Sauver JL, Takahashi PY, Roger VL, Rocca WA, Miller VM, Olson JE, Pathak J, et al. Improvement in cardiovascular risk prediction with electronic health records. J Cardiovasc Transl Res. 2016;9(3):214–22.PubMedPubMedCentralCrossRef Pike MM, Decker PA, Larson NB, St Sauver JL, Takahashi PY, Roger VL, Rocca WA, Miller VM, Olson JE, Pathak J, et al. Improvement in cardiovascular risk prediction with electronic health records. J Cardiovasc Transl Res. 2016;9(3):214–22.PubMedPubMedCentralCrossRef
59.
go back to reference Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, Ballantyne CM, Go AS. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67(18):2118–30.PubMedPubMedCentralCrossRef Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, Ballantyne CM, Go AS. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67(18):2118–30.PubMedPubMedCentralCrossRef
60.
go back to reference Rodondi N, Locatelli I, Aujesky D, Butler J, Vittinghoff E, Simonsick E, Satterfield S, Newman AB, Wilson PWF, Pletcher MJ, et al. Framingham risk score and alternatives for prediction of coronary heart disease in older adults. PLoS One. 2012;7(3):e34287. Rodondi N, Locatelli I, Aujesky D, Butler J, Vittinghoff E, Simonsick E, Satterfield S, Newman AB, Wilson PWF, Pletcher MJ, et al. Framingham risk score and alternatives for prediction of coronary heart disease in older adults. PLoS One. 2012;7(3):e34287.
61.
go back to reference Ryckman EM, Summers RM, Liu J, Munoz del Rio A, Pickhardt PJ. Visceral fat quantification in asymptomatic adults using abdominal CT: is it predictive of future cardiac events? Abdom Imaging. 2015;40(1):222–6.PubMedPubMedCentralCrossRef Ryckman EM, Summers RM, Liu J, Munoz del Rio A, Pickhardt PJ. Visceral fat quantification in asymptomatic adults using abdominal CT: is it predictive of future cardiac events? Abdom Imaging. 2015;40(1):222–6.PubMedPubMedCentralCrossRef
62.
go back to reference Simmons RK, Sharp S, Boekholdt SM, Sargeant LA, Khaw K-T, Wareham NJ, Griffin SJ. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med. 2008;168(11):1209–16.PubMedCrossRef Simmons RK, Sharp S, Boekholdt SM, Sargeant LA, Khaw K-T, Wareham NJ, Griffin SJ. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med. 2008;168(11):1209–16.PubMedCrossRef
63.
go back to reference Simons LA, Simons J, Friedlander Y, McCallum J, Palaniappan L. Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. Med J Aust. 2003;178(3):113–6.PubMedPubMedCentralCrossRef Simons LA, Simons J, Friedlander Y, McCallum J, Palaniappan L. Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. Med J Aust. 2003;178(3):113–6.PubMedPubMedCentralCrossRef
64.
go back to reference Suka M, Sugimori H, Yoshida K. Application of the updated Framingham risk score to Japanese men. Hypertens Res. 2001;24(6):685–9.PubMedCrossRef Suka M, Sugimori H, Yoshida K. Application of the updated Framingham risk score to Japanese men. Hypertens Res. 2001;24(6):685–9.PubMedCrossRef
65.
go back to reference Sussman JB, Wiitala WL, Zawistowski M, Hofer TP, Bentley D, Hayward RA. The veterans affairs cardiac risk score: recalibrating the atherosclerotic cardiovascular disease score for applied use. Med Care. 2017;55(9):864–70.PubMedPubMedCentralCrossRef Sussman JB, Wiitala WL, Zawistowski M, Hofer TP, Bentley D, Hayward RA. The veterans affairs cardiac risk score: recalibrating the atherosclerotic cardiovascular disease score for applied use. Med Care. 2017;55(9):864–70.PubMedPubMedCentralCrossRef
66.
go back to reference Vaidya D, Yanek LR, Moy TF, Pearson TA, Becker LC, Becker DM. Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up. Am J Cardiol. 2007;100(9):1410–5.PubMedPubMedCentralCrossRef Vaidya D, Yanek LR, Moy TF, Pearson TA, Becker LC, Becker DM. Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up. Am J Cardiol. 2007;100(9):1410–5.PubMedPubMedCentralCrossRef
67.
go back to reference Yang X, Li J, Hu D, Chen J, Li Y, Huang J, Liu X, Liu F, Cao J, Shen C, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in chinese population: The China-PAR Project (Prediction for ASCVD Risk in China). Circulation. 2016;134(19):1430–40.PubMedCrossRef Yang X, Li J, Hu D, Chen J, Li Y, Huang J, Liu X, Liu F, Cao J, Shen C, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in chinese population: The China-PAR Project (Prediction for ASCVD Risk in China). Circulation. 2016;134(19):1430–40.PubMedCrossRef
68.
go back to reference Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S76–99.PubMedCrossRef Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S76–99.PubMedCrossRef
69.
go back to reference Knottnerus JA. Diagnostic prediction rules: principles, requirements and pitfalls. Prim Care. 1995;22(2):341–63.PubMed Knottnerus JA. Diagnostic prediction rules: principles, requirements and pitfalls. Prim Care. 1995;22(2):341–63.PubMed
70.
go back to reference Vergouwe Y, Moons KG, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010;172(8):971–80.PubMedPubMedCentralCrossRef Vergouwe Y, Moons KG, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010;172(8):971–80.PubMedPubMedCentralCrossRef
71.
go back to reference Debray TP, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KG. A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2015;68(3):279–89. Debray TP, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KG. A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2015;68(3):279–89.
72.
go back to reference Paynter NP, Everett BM, Cook NR. Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? Clin Chem. 2014;60(1):88–97.PubMedCrossRef Paynter NP, Everett BM, Cook NR. Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? Clin Chem. 2014;60(1):88–97.PubMedCrossRef
73.
go back to reference Ridker PM, Cook NR. The Pooled Cohort Equations 3 Years On: Building a Stronger Foundation. Circulation. 2016;134(23):1789–91.PubMedCrossRef Ridker PM, Cook NR. The Pooled Cohort Equations 3 Years On: Building a Stronger Foundation. Circulation. 2016;134(23):1789–91.PubMedCrossRef
74.
go back to reference Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2(7):517–26.PubMedCrossRef Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2(7):517–26.PubMedCrossRef
75.
go back to reference Pajouheshnia R, Peelen LM, Moons KGM, Reitsma JB, Groenwold RHH. Accounting for treatment use when validating a prognostic model: a simulation study. BMC Med Res Methodol. 2017;17(1):103. Pajouheshnia R, Peelen LM, Moons KGM, Reitsma JB, Groenwold RHH. Accounting for treatment use when validating a prognostic model: a simulation study. BMC Med Res Methodol. 2017;17(1):103.
76.
go back to reference Pajouheshnia R, Damen JA, Groenwold RH, Moons KG, Peelen LM. Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies. Diagnostic Rognostic Res. 2017;1(1):15.CrossRef Pajouheshnia R, Damen JA, Groenwold RH, Moons KG, Peelen LM. Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies. Diagnostic Rognostic Res. 2017;1(1):15.CrossRef
77.
go back to reference Rospleszcz S, Thorand B, de Las Heras Gala T, Meisinger C, Holle R, Koenig W, Mansmann U, Peters A. Temporal trends in cardiovascular risk factors and performance of the Framingham Risk Score and the pooled cohort equations. J Epidemiol Community Health. 2019;73(1):19–25.PubMedCrossRef Rospleszcz S, Thorand B, de Las Heras Gala T, Meisinger C, Holle R, Koenig W, Mansmann U, Peters A. Temporal trends in cardiovascular risk factors and performance of the Framingham Risk Score and the pooled cohort equations. J Epidemiol Community Health. 2019;73(1):19–25.PubMedCrossRef
78.
go back to reference Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55–63.PubMedCrossRef Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55–63.PubMedCrossRef
79.
go back to reference Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73.PubMedCrossRef Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73.PubMedCrossRef
80.
go back to reference Groenwold RH, Moons KG, Pajouheshnia R, Altman DG, Collins GS, Debray TP, Reitsma JB, Riley RD, Peelen LM. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. J Clin Epidemiol. 2016;78:90–100.PubMedCrossRef Groenwold RH, Moons KG, Pajouheshnia R, Altman DG, Collins GS, Debray TP, Reitsma JB, Riley RD, Peelen LM. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. J Clin Epidemiol. 2016;78:90–100.PubMedCrossRef
81.
go back to reference Muntner P, Safford MM, Cushman M, Howard G. Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129(2):266–7.PubMedCrossRef Muntner P, Safford MM, Cushman M, Howard G. Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129(2):266–7.PubMedCrossRef
83.
go back to reference Goff DC Jr, D’Agostino RB Sr, Pencina M, Lloyd-Jones DM. Calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;163(1):68.PubMedCrossRef Goff DC Jr, D’Agostino RB Sr, Pencina M, Lloyd-Jones DM. Calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;163(1):68.PubMedCrossRef
85.
go back to reference Cook NR, Ridker PM. Response to Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129(2):268–9.PubMedCrossRef Cook NR, Ridker PM. Response to Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129(2):268–9.PubMedCrossRef
86.
go back to reference Thakkar J, Heeley EL, Chalmers J, Chow CK. Inaccurate risk perceptions contribute to treatment gaps in secondary prevention of cardiovascular disease. Intern Med J. 2016;46(3):339–46.PubMedCrossRef Thakkar J, Heeley EL, Chalmers J, Chow CK. Inaccurate risk perceptions contribute to treatment gaps in secondary prevention of cardiovascular disease. Intern Med J. 2016;46(3):339–46.PubMedCrossRef
87.
go back to reference Riley RD, Ensor J, Snell KI, Debray TP, Altman DG, Moons KG, Collins GS. External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges. BMJ. 2016;353:i3140.PubMedPubMedCentralCrossRef Riley RD, Ensor J, Snell KI, Debray TP, Altman DG, Moons KG, Collins GS. External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges. BMJ. 2016;353:i3140.PubMedPubMedCentralCrossRef
88.
go back to reference Vergouwe Y, Nieboer D, Oostenbrink R, Debray TP, Murray GD, Kattan MW, Koffijberg H, Moons KG, Steyerberg EW. A closed testing procedure to select an appropriate method for updating prediction models. Stat Med. 2017;36(28):4529–39. Vergouwe Y, Nieboer D, Oostenbrink R, Debray TP, Murray GD, Kattan MW, Koffijberg H, Moons KG, Steyerberg EW. A closed testing procedure to select an appropriate method for updating prediction models. Stat Med. 2017;36(28):4529–39.
89.
go back to reference Grundy SM, D'Agostino RB Sr, Mosca L, Burke GL, Wilson PW, Rader DJ, Cleeman JI, Roccella EJ, Cutler JA, Friedman LM. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation. 2001;104(4):491–6. Grundy SM, D'Agostino RB Sr, Mosca L, Burke GL, Wilson PW, Rader DJ, Cleeman JI, Roccella EJ, Cutler JA, Friedman LM. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation. 2001;104(4):491–6.
90.
go back to reference Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, Azizi F, Cifkova R, Di Cesare M, Eriksen L, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015;3(5):339–55.PubMedCrossRef Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, Azizi F, Cifkova R, Di Cesare M, Eriksen L, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015;3(5):339–55.PubMedCrossRef
91.
go back to reference van Dis I, Kromhout D, Geleijnse JM, Boer JM, Verschuren WM. Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil. 2010;17(2):244–9.PubMedCrossRef van Dis I, Kromhout D, Geleijnse JM, Boer JM, Verschuren WM. Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil. 2010;17(2):244–9.PubMedCrossRef
92.
go back to reference De Bacquer D, De Backer G. Predictive ability of the SCORE Belgium risk chart for cardiovascular mortality. Int J Cardiol. 2010;143(3):385–90.PubMedCrossRef De Bacquer D, De Backer G. Predictive ability of the SCORE Belgium risk chart for cardiovascular mortality. Int J Cardiol. 2010;143(3):385–90.PubMedCrossRef
93.
go back to reference Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibrating the SCORE cardiovascular risk chart for use in Spain. Rev Esp Cardiol. 2007;60(5):476–85.PubMedCrossRef Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibrating the SCORE cardiovascular risk chart for use in Spain. Rev Esp Cardiol. 2007;60(5):476–85.PubMedCrossRef
94.
go back to reference Usher-Smith JA, Silarova B, Schuit E, Gm Moons K, Griffin SJ. Impact of provision of cardiovascular disease risk estimates to healthcare professionals and patients: a systematic review. BMJ Open. 2015;5(10):e008717.PubMedPubMedCentralCrossRef Usher-Smith JA, Silarova B, Schuit E, Gm Moons K, Griffin SJ. Impact of provision of cardiovascular disease risk estimates to healthcare professionals and patients: a systematic review. BMJ Open. 2015;5(10):e008717.PubMedPubMedCentralCrossRef
95.
go back to reference Studzinski K, Tomasik T, Krzyszton J, Jozwiak J, Windak A. Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews. BMC Cardiovasc Disord. 2019;19(1):11.PubMedPubMedCentralCrossRef Studzinski K, Tomasik T, Krzyszton J, Jozwiak J, Windak A. Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews. BMC Cardiovasc Disord. 2019;19(1):11.PubMedPubMedCentralCrossRef
96.
go back to reference Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Smith GD, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013(1):Cd004816. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Smith GD, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013(1):Cd004816.
97.
go back to reference Lackland DT, Elkind MS, D’Agostino R Sr, Dhamoon MS, Goff DC Jr, Higashida RT, McClure LA, Mitchell PH, Sacco RL, Sila CA, et al. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(7):1998–2027. Lackland DT, Elkind MS, D’Agostino R Sr, Dhamoon MS, Goff DC Jr, Higashida RT, McClure LA, Mitchell PH, Sacco RL, Sila CA, et al. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(7):1998–2027.
98.
go back to reference Damen JAAG, Debray TPA, Pajouheshnia R, Reitsma JB, Scholten RJPM, Moons KGM, Hooft L. Empirical evidence of the impact of study characteristics on the performance of prediction models: a meta-epidemiological study. BMJ Open. 2019;9(4):e026160. Damen JAAG, Debray TPA, Pajouheshnia R, Reitsma JB, Scholten RJPM, Moons KGM, Hooft L. Empirical evidence of the impact of study characteristics on the performance of prediction models: a meta-epidemiological study. BMJ Open. 2019;9(4):e026160.
Metadata
Title
Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis
Authors
Johanna A. Damen
Romin Pajouheshnia
Pauline Heus
Karel G. M. Moons
Johannes B. Reitsma
Rob J. P. M. Scholten
Lotty Hooft
Thomas P. A. Debray
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2019
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-019-1340-7

Other articles of this Issue 1/2019

BMC Medicine 1/2019 Go to the issue